Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Binding of Vaccine and Poly(DL-lactide-co-glycolide) Nanoparticle Modified with Anionic Surfactant

음이온성 유화제로 수식된 폴리락티드/글리코리드 공중합체 나노 입자와 백신의 결합성

  • Choi, Min-Soo (Advanced Materials Division, Korea Research Institute of Chemical Technology) ;
  • Park, Eun-Seok (College of Pharmacy, Sung Kyun Kwan University) ;
  • Chi, Sang-Cheol (College of Pharmacy, Sung Kyun Kwan University) ;
  • Shin, Byung-Cheol (Advanced Materials Division, Korea Research Institute of Chemical Technology)
  • 최민수 (한국화학연구원 나노생체재료팀) ;
  • 박은석 (성균관대학교 제약학과) ;
  • 지상철 (성균관대학교 제약학과) ;
  • 신병철 (한국화학연구원 나노생체재료팀)
  • Published : 2004.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Recently, studies on intranasal mucosa delivery of influenza vaccine have been actively developed because of lack of pain and ease of administration. We studied on preparation of nanoparticle delivery system using biodegradable polymer as a poly(DL-lactide-co-glycolide) (PLGA) and their binding characteristics with vaccine. Three kinds of PLGA nanoparticles were prepared by spontaneous emulsification solvent diffusion (SESD) method using sodium dodecyl sulfate and sodium laurate as an anionic surfactant and Lutrol F68 (polyethylene glycol-block-polypropylene glycol copolymer) as a nonionic surfactant. The 5-aminofluorescein labeled vaccine was coated on the surface of nanoparticles by ionic complex. The complexes between vaccine and nanoparticles were confirmed by change of the size. After vaccine coating on the surface of anionic nanoparticles, particle size was increased from 174 to 1,040 nm. However the size of nonionic nanoparticles was not more increased than size of anionic nanoparticles. The amount of coated vaccine on the surface of PLGA nanoparticles was $14.32\;{\mu}g/mg$ with sodium dodecyl sulfate, $12.41\;{\mu}g/mg$ with sodium laurate, and $9.47{\mu}g/mg$ with Lutrol F68, respectively. In conclusion, prepared nanoparticles in this study is possible to use as a virus-like nanoparticles and it could be accept in the field of influenza vaccine delivery system.

Keywords

References

  1. S.S. Davis, Nasal vaccines, Advanced Drug Del. Rev., 51, 21-42 (2001) https://doi.org/10.1016/S0169-409X(01)00162-4
  2. R. Glueck, Review of intranasal influenza vaccine, Advanced Drug Det. Rev., 51, 203-211 (2001) https://doi.org/10.1016/S0169-409X(01)00174-0
  3. C.W. Potter and R. Jennings, Intranasal immunization with inactivated influenza Vaccine, Pharm. Sci. & Tech. Today, 2, 402-408 (1999) https://doi.org/10.1016/S1461-5347(99)00194-7
  4. T.G. Boyce and G.A. Poland, Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum, Biomedic. & Pharmacother., 54, 210-218 (2000) https://doi.org/10.1016/S0753-3322(00)89027-7
  5. L.A. Jackson, S.J. Holmes, P.M. Mendelman, L. Huggins, I. Cho and J. Rhorer, Satety of a trivalent live attenuated intranasal influenza vaccine, FluMist[TM], administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions, Vaccine, 17, 1905-1909 (1999) https://doi.org/10.1016/S0264-410X(98)00471-X
  6. W.E.P. Beyer, A.M. Palache, J.C. de Jong and A.D.M.E.Osterhaus, Cold-adapted live influenza vaccine Vs inactivated vaccine: systemic vaccine reaction, local and systemic antibody response, and vaccine efficacy A meta-analysis, Vaccine, 20, 1340-1353 (2002) https://doi.org/10.1016/S0264-410X(01)00471-6
  7. R.B. Belshe, W.C. Gruber, P.M. Mendelman, I. Cho, K. Reisinger, S.L. Block, J. Wittes, D. lacuzio, P. Piedra, J. Treanor, J. King, K. Kotloff, D.I. Bernstein, F.G. Hayden, K. Zangwill, L. Yan and M. Wolff, Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine, J. Pediatr, 136, 168-175 (2000) https://doi.org/10.1016/S0022-3476(00)70097-7
  8. B. Morein and K.L. Bengtsson, Immunomodulation by iscoms, immune stimulating complexes, Methods, 19, 94-102 (1999) https://doi.org/10.1006/meth.1999.0833
  9. L. Illum, I.J. Gill, M. Hinchcliffe M, A.N. Fisher and S.S. Davis, Chitosan as a novel nasal delivery system for vaccine, Advanced Drug DeI. Rev., 51, 81-96 (2001) https://doi.org/10.1016/S0169-409X(01)00171-5
  10. K, Hashigucci, H. Ogawa, T. Ishidate, R. Yamashita, H. Kamiya, K. Watanabe and N. Hattori, Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-1bile enterotoxin B subunit containing a trace amount of the holotoxin, Vaccine, 14, 113-119 (1996) https://doi.org/10.1016/0264-410X(95)00174-Y
  11. U.-R. Gluck and J.O. Gebbers, Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-1bile toxin in adult volunteers, Virology, 73. 7780-7786 (1999)
  12. R. Gluck, R. Mischler, P. Durrer, E. Furer, A.B. Lang, C. Herzog and S.J. Cryz, Safety and immunogenicity of intranasally administered inactivated trivalent Virosomeformulated influenza vaccine containing Escherichia coli heat-1bile toxin as a mucosal adjuvant in young adult and elderlysubjects, J. Infectious Dia., 181, 1129-1132 (2000) https://doi.org/10.1086/315337
  13. T. Riley, S. Stolnik, C.R. Heald, C.D. Xiong, M.C. Gamett, L. Illum and S.S. Davis, Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethyleneglycol) (PLA-PEG) block copolymers as drug delivery vehicles, Langmuir : The ACS J. Surfaces and CoIIoids, 17, 3168-3174 (2001)
  14. D.T. O'Hagan, Microparticles and polymers for the mucosal delivery of vaccines, Advanced Drug Det. Rev., 34, 305-320 (1998) https://doi.org/10.1016/S0169-409X(98)00045-3
  15. V. Michael and D.T. O'Hagan, Microparticles for intranasal immunization, Advanced Drug Del. Rev., 51, 127-141 (2001) https://doi.org/10.1016/S0169-409X(01)00167-3
  16. A. Vila, A. Sanchez, M. Tobio, C. Evora, I. Soriano, 0. Mc-Callion and M.J. Alonso, PLA-PEG nano and microparticles as carriers for nasal vaccine delivery, Pharm. Res., 15, 270-275(1998) https://doi.org/10.1023/A:1011922819926
  17. H. Murakami, M. Kobayashi, H. Takeuchi and Y. Kawashima, Preparation of poly(DL-Lactide-co-glycolide) nanoparticles by modified spotaneous emulsificadon solvent diffusion method, Int. J. Pharm., 187, 143-152 (1999) https://doi.org/10.1016/S0378-5173(99)00187-8
  18. O. Hiraku and M. Yoshiharu, Biodegradation and distribution of water-soluble chitosan in mice, Biomaterials, 20, 175-182 (1999) https://doi.org/10.1016/S0142-9612(98)00159-8
  19. S.J. Park, S.H. Kim, I.R. Lee, H.B. Lee and S.K. Hong, Preparation and characterization of biodegradable poly(\epsilon-caprolactone) microcapsules containing erythromycin by emulsion solvent evaporation technique Polymer(Korea), 26(3), 326 (2002)
  20. H. Murakami, Y. Kawashima, T. Niwa, T. Hino, H. Takeuchi and M. Kobayashi, Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(DL-lactide-co-glycolide) nanoparticles, Int. J. Pharm., 149, 43-49 (1997) https://doi.org/10.1016/S0378-5173(96)04854-5